InnoCare Begins Global Phase II Trial of TYK2 Inhibitor Soficitinib for Prurigo Nodularis

InnoCare Pharma has dosed the first patient in its global Phase II clinical trial of Soficitinib (ICP-332), a selective TYK2 inhibitor being developed for prurigo nodularis. The study, launched in China, advances the company’s strategy to address chronic inflammatory skin diseases with novel immunomodulatory therapies.

Advancing a Broad Autoimmune Dermatology Pipeline
Soficitinib targets key cytokine pathways, including IL-4, IL-13, and IL-31, implicated in neurogenic itch and skin inflammation. The candidate is also in development for atopic dermatitis, vitiligo, and urticaria. Prior Phase II data in moderate-to-severe atopic dermatitis showed strong efficacy and safety, underscored by a late-breaking oral presentation at the American Academy of Dermatology meeting.

Growing Market Need for Prurigo Nodularis Therapies
Prurigo nodularis affects an estimated 10 million people globally and continues to be an underserved dermatologic condition. With the market valued at US$2 billion in 2024 and projected to reach US$3 billion by 2034, InnoCare’s latest milestone reinforces its commitment to accelerating global development of innovative autoimmune treatments.